University of Salamanca at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
University of Salamanca takes part in 2 sessions at ASH 2026 in New Orleans. Its program centres on multiple myeloma. It covers BCMA-targeted bispecific antibodies from biology to real-world use, and tailoring treatment for newly diagnosed patients.
| Organization | ASH 2026 Attendance |
|---|---|
University of Salamanca Salamanca, Spain | |
Public university in Salamanca, Spain, one of Europe's oldest, with a medical school. | Symposium Fri Dec 11 7:00am–10:00am Anti-BCMA Bispecific Antibodies in Multiple Myeloma: From Biology to Real-World Implementation Bispecific antibodies targeting B-cell maturation antigen in myeloma, from mechanism and resistance to trial data, outpatient dosing, and infection prevention. Symposium Fri Dec 11 11:00am–2:00pm Medical Crossfire®: Translating Evolving Standards of Care in Newly Diagnosed Multiple Myeloma Into Individualized Treatment Strategies Choosing four-drug starting regimens for newly diagnosed myeloma, using residual disease tests to guide therapy, and managing new side effects. |
Find decision makers at University of Salamanca
Tell us what you sell and we’ll find the people at University of Salamanca most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction